Our unique business model prioritises impact over profit. By focusing on medicines already in the clinical development phase, we increase the probability of success, shorten the time to impact, and minimise the potential financial loss due to failure. After development we shepherd our medicines through the relevant regulatory pathways and hold and maintain the respective authorisations to ensure access by those who need the medicines most.

Between 2005 and 2024, more spacecraft were sent to the moon than new U.S. FDA-approved medicines were developed for neglected diseases and tuberculosis. We’re addressing this innovation gap by developing improved treatments that can transform health outcomes for people in low- and middle-income communities.

Source: Ashigbie et al 2025 Nature Reviews Drug Discovery https://en.wikipedia.org/wiki/List_of_mission_to_the_Moon#2000

We’re already making progress in addressing global health inequities, but we’re just one piece of a larger puzzle. Our work and its impact on global health is only made possible through productive partnerships with industry, research institutes, governments, impact investors and donors.